Truist analyst David MacDonald raised the firm’s price target on Tenet Healthcare (THC) to $205 from $190 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results for Healthcare Services. The quarter should reflect an ongoing mixed, sector-dependent backdrop across the firm’s coverage universe with a focus on selectivity and utilization-leveraged names best positioned, and Managed Care continuing to face challenges, the analyst tells investors in a research note. Truist adds that it remains bullish on core demand drivers for the industry however and also believes that the Reconciliation Bill has provided increased clarity around regulatory framework.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- CMS announces proposed rules for hospital payments in 2026
- Tenet Healthcare price target raised to $194 from $184 at Mizuho
- Fuzzy Panda Research says short Tenet Healthcare
- RBC a buyer of hospital stocks on White House memo selloff
- HCA Healthcare price target raised to $410 from $355 at Morgan Stanley